Skip to content
10-Q

Quarterly Report

ACHILLION PHARMACEUTICALS INC

0001193125-19-142950

← back to feed
Filed
May 9, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · May 1, 2019 138.73M sh
Capex Q1 2019 · Mar 31, 2019 $70K
Capex Q1 2019 · Mar 31, 2018 $178K
Operating Cash Flow Q1 2019 · Mar 31, 2019 −$17.73M
Operating Cash Flow Q1 2019 · Mar 31, 2018 −$24.1M
Cash And Equivalents Q1 2019 · Mar 31, 2019 $49.49M
Cash And Equivalents Q1 2019 · Dec 31, 2018 $49.83M
Stockholders Equity Q1 2019 · Mar 31, 2019 $248.94M
Stockholders Equity Q1 2019 · Dec 31, 2018 $266.01M
Stockholders Equity Q1 2019 · Mar 31, 2018 $307.27M
Stockholders Equity Q1 2019 · Dec 31, 2017 $324.52M
Current Liabilities Q1 2019 · Mar 31, 2019 $13.18M
Current Liabilities Q1 2019 · Dec 31, 2018 $11.83M
Total Liabilities Q1 2019 · Mar 31, 2019 $13.74M
Total Liabilities Q1 2019 · Dec 31, 2018 $11.85M
Current Assets Q1 2019 · Mar 31, 2019 $259.09M
Current Assets Q1 2019 · Dec 31, 2018 $275.38M
Total Assets Q1 2019 · Mar 31, 2019 $262.68M
Total Assets Q1 2019 · Dec 31, 2018 $277.86M
Sga Expense Q1 2019 · Mar 31, 2019 $5.16M
Sga Expense restated Q1 2019 · Mar 31, 2018 $6.02M
Rd Expense Q1 2019 · Mar 31, 2019 $14.82M
Rd Expense restated Q1 2019 · Mar 31, 2018 $14.05M
Net Income Q1 2019 · Mar 31, 2019 −$18.96M
Net Income Q1 2019 · Mar 31, 2018 −$20.59M
Operating Income Q1 2019 · Mar 31, 2019 −$20.63M
Operating Income Q1 2019 · Mar 31, 2018 −$21.82M
Revenue Q1 2019 · Mar 31, 2019 $0
Revenue Q1 2019 · Mar 31, 2018 $0
Short Term Debt Q1 2019 · Dec 31, 2018 $131K